Your browser doesn't support javascript.
loading
A multisociety Delphi consensus statement on new fatty liver disease nomenclature.
Rinella, Mary E; Lazarus, Jeffrey V; Ratziu, Vlad; Francque, Sven M; Sanyal, Arun J; Kanwal, Fasiha; Romero, Diana; Abdelmalek, Manal F; Anstee, Quentin M; Arab, Juan Pablo; Arrese, Marco; Bataller, Ramon; Beuers, Ulrich; Boursier, Jerome; Bugianesi, Elisabetta; Byrne, Christopher D; Narro, Graciela E Castro; Chowdhury, Abhijit; Cortez-Pinto, Helena; Cryer, Donna R; Cusi, Kenneth; El-Kassas, Mohamed; Klein, Samuel; Eskridge, Wayne; Fan, Jiangao; Gawrieh, Samer; Guy, Cynthia D; Harrison, Stephen A; Kim, Seung Up; Koot, Bart G; Korenjak, Marko; Kowdley, Kris V; Lacaille, Florence; Loomba, Rohit; Mitchell-Thain, Robert; Morgan, Timothy R; Powell, Elisabeth E; Roden, Michael; Romero-Gómez, Manuel; Silva, Marcelo; Singh, Shivaram Prasad; Sookoian, Silvia C; Spearman, C Wendy; Tiniakos, Dina; Valenti, Luca; Vos, Miriam B; Wong, Vincent Wai-Sun; Xanthakos, Stavra; Yilmaz, Yusuf; Younossi, Zobair.
Afiliação
  • Rinella ME; University of Chicago, Pritzker School of Medicine, Chicago, Illinois, USA. Electronic address: mrinella@bsd.uchicago.edu.
  • Lazarus JV; City University of New York Graduate School of Public Health and Health Policy (CUNY SPH), New York, New York, USA; Barcelona Institute for Global Health (ISGlobal), Hospital Clinic, University of Barcelona, Barcelona, Spain.
  • Ratziu V; Sorbonne Université, ICAN Institute for Metabolism and Nutrition, Hospital Pitié-Salpêtrière, Paris, France.
  • Francque SM; Department of Gastroenterology Hepatology, Antwerp University Hospital, Edegem, Belgium; InflaMed Centre of Excellence, Laboratory for Experimental Medicine and Paediatrics, Translational Sciences in Inflammation and Immunology, Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk
  • Sanyal AJ; Virginia Commonwealth University, Richmond, Virginia, USA.
  • Kanwal F; Sections of Gastroenterology and Hepatology and Health Services Research, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA; VA HSR&D Center for Innovations in Quality, Effectiveness, and Safety (IQuESt), Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas, U
  • Romero D; City University of New York Graduate School of Public Health and Health Policy (CUNY SPH), New York, New York, USA.
  • Abdelmalek MF; Mayo Clinic, Rochester, Minnesota, USA.
  • Anstee QM; Translational & Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK; Newcastle NIHR Biomedical Research Center, Newcastle upon Tyne Hospitals NHS Trust, Newcastle upon Tyne, UK.
  • Arab JP; Division of Gastroenterology, Department of Medicine, Schulich School of Medicine, Western University & London Health Sciences Centre, London, Ontario, Canada; Department of Epidemiology and Biostatistics, Schulich School of Medicine, Western University, London, Ontario, Canada; Departamento de
  • Arrese M; Departamento de Gastroenterologia, Escuela de Medicina, Pontificia Universidad Catolica de Chile, Santiago, Chile; Latin American Association for the Study of the Liver (ALEH) Santiago, Chile.
  • Bataller R; Liver Unit, Hospital Clinic, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • Beuers U; Department of Gastroenterology & Hepatology, Tytgat Institute for Liver and Intestinal Research, Amsterdam University Medical Centers, Location AMC, Amsterdam, The Netherlands.
  • Boursier J; Hepato-Gastroenterology and Digestive Oncology Department, Angers University Hospital, Angers, France & HIFIH Laboratory UPRES EA3859, SFR 4208, Angers University, Angers, France.
  • Bugianesi E; Department of Medical Sciences, University of Torino, Torino, Italy.
  • Byrne CD; Nutrition and Metabolism, Faculty of Medicine, University of Southampton, Southampton, UK; National Institute for Health and Care Research Southampton Biomedical Research Centre, University Hospital Southampton, Southampton, UK.
  • Narro GEC; Latin American Association for the Study of the Liver (ALEH) Santiago, Chile; Hepatology and Transplant Unit, Hospital Médica Sur, Mexico City, Mexico; Department of Gastroenterology, National Institute of Medical Sciences and Nutrition "Salvador Zubirán" Mexico City, Mexico.
  • Chowdhury A; Indian Institute of Liver and Digestive Sciences, Sonarpur, Kolkata, India; John C. Martin Centre for Liver Research and Innovations, Sonarpur, Kolkata, India.
  • Cortez-Pinto H; Clínica Universitária de Gastrenterologia, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal.
  • Cryer DR; Global Liver Institute, Washington, District of Columbia, USA.
  • Cusi K; Division of Endocrinology, Diabetes and Metabolism, The University of Florida, Gainesville, Florida, USA.
  • El-Kassas M; Endemic Medicine Department, Faculty of Medicine, Helwan University, Cairo, Egypt.
  • Klein S; Washington University School of Medicine, St. Louis, Missouri, USA.
  • Eskridge W; Fatty Liver Foundation, Boise, Idaho, USA.
  • Fan J; Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Gawrieh S; Division of Gastroenterology and Hepatology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Guy CD; Department of Pathology, Duke Health Systems, Durham, North Carolina, USA.
  • Harrison SA; Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
  • Kim SU; Yonsei University College of Medicine, Seoul, Korea.
  • Koot BG; Department of Pediatric Gastroenterology, Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Korenjak M; European Liver Patients' Association, Brussels, Belgium.
  • Kowdley KV; Liver Institute Northwest Elson S. Floyd College of Medicine Washington State University Seattle, Washington, USA.
  • Lacaille F; Hôpital Universitaire Necker-Enfants Maladies, Paris, France.
  • Loomba R; NAFLD Research Center, Division of Gastroenterology and Hepatology, Department of Medicine, University of California at San Diego, La Jolla, California, USA.
  • Mitchell-Thain R; PBC Foundation, Liver Patients International, Edinburgh, Scotland.
  • Morgan TR; Medical Service, VA Long Beach Healthcare System, Long Beach, California, USA; Department of Medicine, University of California, Irvine, California, USA.
  • Powell EE; Centre for Liver Disease Research, Faculty of Medicine, The University of Queensland, Translational Research Institute, Brisbane, Queensland, Australia; QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia; Department of Gastroenterology and Hepatology, Princess Alexandra Hospit
  • Roden M; Department of Endocrinology and Diabetology, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf, Düsseldorf, Germany; Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University Düsseldorf, Düssel
  • Romero-Gómez M; Digestive Diseases and Ciberehd, Virgen del Rocio University Hospital, Institute of Biomedicine of Seville (CSIC/HUVR/US), University of Seville, Seville, Spain.
  • Silva M; Austral University Hospital, Buenos Aires, Argentina.
  • Singh SP; Kalinga Gastroenterology Foundation, Cuttack, Odisha, India.
  • Sookoian SC; Departamento de Gastroenterologia, Escuela de Medicina, Pontificia Universidad Catolica de Chile, Santiago, Chile; Clinical and Molecular Hepatology, Centro de Altos Estudios en Ciencias Humanas y de la Salud (CAECIHS), Universidad Abierta Interamericana, Consejo Nacional de Investigaciones Científi
  • Spearman CW; Division of Hepatology, Department of Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
  • Tiniakos D; Translational & Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK; Department of Pathology, Aretaieion Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
  • Valenti L; Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy; Biological Resource Center Unit, Precision Medicine lab, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milano, Milan, Italy.
  • Vos MB; Division of Gastroenterology, Department of Paediatrics, Hepatology and Nutrition, Emory University and Children's Healthcare of Atlanta, Atlanta, Georgia, USA.
  • Wong VW; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China.
  • Xanthakos S; Department of paediatrics, Division of Gastroenterology Hepatology and Nutrition, Cincinnati Children's, Nonalcoholic Steatohepatitis Center, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
  • Yilmaz Y; Department of Gastroenterology, School of Medicine, Recep Tayyip Erdogan University, Rize, Turkey.
  • Younossi Z; Inova Medicine, Inova Health System, Falls Church, Virginia, USA; Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, VA, United States; Center for Liver Disease, Department of Medicine, Inova Fairfax Medical Campus, Falls Church, VA, United States.
Ann Hepatol ; 29(1): 101133, 2024.
Article em En | MEDLINE | ID: mdl-37364816
The principal limitations of the terms NAFLD and NASH are the reliance on exclusionary confounder terms and the use of potentially stigmatising language. This study set out to determine if content experts and patient advocates were in favor of a change in nomenclature and/or definition. A modified Delphi process was led by three large pan-national liver associations. The consensus was defined a priori as a supermajority (67%) vote. An independent committee of experts external to the nomenclature process made the final recommendation on the acronym and its diagnostic criteria. A total of 236 panelists from 56 countries participated in 4 online surveys and 2 hybrid meetings. Response rates across the 4 survey rounds were 87%, 83%, 83%, and 78%, respectively. Seventy-four percent of respondents felt that the current nomenclature was sufficiently flawed to consider a name change. The terms "nonalcoholic" and "fatty" were felt to be stigmatising by 61% and 66% of respondents, respectively. Steatotic liver disease was chosen as an overarching term to encompass the various aetiologies of steatosis. The term steatohepatitis was felt to be an important pathophysiological concept that should be retained. The name chosen to replace NAFLD was metabolic dysfunction-associated steatotic liver disease. There was consensus to change the definition to include the presence of at least 1 of 5 cardiometabolic risk factors. Those with no metabolic parameters and no known cause were deemed to have cryptogenic steatotic liver disease. A new category, outside pure metabolic dysfunction-associated steatotic liver disease, termed metabolic and alcohol related/associated liver disease (MetALD), was selected to describe those with metabolic dysfunction-associated steatotic liver disease, who consume greater amounts of alcohol per week (140-350 g/wk and 210-420 g/wk for females and males, respectively). The new nomenclature and diagnostic criteria are widely supported and nonstigmatising, and can improve awareness and patient identification.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Hepatopatia Gordurosa não Alcoólica Tipo de estudo: Guideline / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male Idioma: En Revista: Ann Hepatol Assunto da revista: GASTROENTEROLOGIA Ano de publicação: 2024 Tipo de documento: Article País de publicação: México

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Hepatopatia Gordurosa não Alcoólica Tipo de estudo: Guideline / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male Idioma: En Revista: Ann Hepatol Assunto da revista: GASTROENTEROLOGIA Ano de publicação: 2024 Tipo de documento: Article País de publicação: México